Sunovion wins FDA nod for inhaled COPD therapy

The FDA has approved Sunovion Pharmaceutical‘s Lonhala Magnair system for the long-term treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported today.

The drug-device combo, also known as Sun-101/eFlow, is the first nebulized long-acting muscarinic antagonist approved for the treatment of COPD in the U.S. The system includes a portable nebulizer that delivers the drug in two to three minutes and allows the user to breathe normally while the drug is administered.

Get the full story at our sister site, Drug Delivery Business News.

The post Sunovion wins FDA nod for inhaled COPD therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2AeSn3S